STOCK TITAN

Kymera (NASDAQ: KYMR) CBO sells 5,000 shares and exercises 5,000 options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Kymera Therapeutics Chief Business Officer Noah Goodman reported an exercise-and-sell transaction in company stock. He exercised stock options for 5,000 shares of Common Stock at an exercise price of $21.05 per share, then sold 5,000 shares in two open-market sales at prices of $119.00 and $109.00 per share.

After these transactions, he directly holds 50,195.438 shares of Common Stock and 90,000 stock options. The filing notes that the sales were effected under a pre-arranged Rule 10b5-1 trading plan dated December 10, 2025.

Positive

  • None.

Negative

  • None.
Insider Goodman Noah
Role Chief Business Officer
Sold 5,000 shs ($570K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 5,000 $0.00 --
Exercise Common Stock 5,000 $21.05 $105K
Sale Common Stock 2,500 $109.00 $273K
Sale Common Stock 2,500 $119.00 $298K
Holdings After Transaction: Stock Option (Right to Buy) — 90,000 shares (Direct, null); Common Stock — 55,195.438 shares (Direct, null)
Footnotes (1)
  1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Twenty-five percent (25%) of the shares underlying this stock option vested on April 8, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date.
Shares sold at $119 2,500 shares at $119.00 Common Stock open-market sale on 2026-06-25
Shares sold at $109 2,500 shares at $109.00 Common Stock open-market sale on 2026-06-25
Options exercised 5,000 shares at $21.05 Stock option exercise into Common Stock
Shares held after 50,195.438 shares Direct Common Stock ownership after transactions
Options remaining 90,000 stock options Direct option holdings after reported exercise
Rule 10b5-1 plan date December 10, 2025 Pre-arranged trading plan governing the sales
Option expiration April 7, 2035 Expiration date of the exercised stock option grant
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action: "open-market sale" with transaction code "S""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" for the derivative transaction"
Exercise or conversion of derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security" for code "M""
vesting financial
"shares underlying this stock option vested on April 8, 2026, with the remainder vesting in thirty-six equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Goodman Noah

(Last)(First)(Middle)
500 NORTH BEACON STREET
4TH FLOOR

(Street)
WATERTOWN MASSACHUSETTS 02472

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Business Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/25/2026M(1)5,000A$21.0555,195.438D
Common Stock06/25/2026S(1)2,500D$10952,695.438D
Common Stock06/25/2026S(1)2,500D$11950,195.438D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$21.0506/25/2026M(1)5,000 (2)04/07/2035Common Stock5,000$090,000D
Explanation of Responses:
1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person.
2. Twenty-five percent (25%) of the shares underlying this stock option vested on April 8, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date.
/s/ Bruce Jacobs, as Attorney-in-Fact06/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Kymera (KYMR) Chief Business Officer report?

Kymera’s Chief Business Officer Noah Goodman reported exercising options for 5,000 shares and selling 5,000 shares of Common Stock in open-market transactions. These trades combined an option exercise with share sales on the same date.

How many Kymera (KYMR) shares did the CBO sell and at what prices?

Noah Goodman sold a total of 5,000 Kymera Common Stock shares, split into two 2,500-share open-market sales. The reported sale prices were $119.00 per share and $109.00 per share on the same transaction date.

What stock options did the Kymera (KYMR) CBO exercise in this Form 4?

He exercised stock options covering 5,000 shares of Kymera Common Stock at an exercise price of $21.05 per share. These options are part of a larger grant with 25% vesting on April 8, 2026 and the remainder vesting monthly thereafter.

How many Kymera (KYMR) shares does the CBO hold after these transactions?

Following the reported transactions, Noah Goodman directly holds 50,195.438 shares of Kymera Common Stock. He also holds 90,000 stock options, giving him a continued significant equity position in the company after the exercise-and-sell activity.

Were the Kymera (KYMR) insider stock sales under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025. Such pre-arranged plans automate trades over time, reducing the significance of short-term market timing for these sales.